WHEAT RIDGE, CO--(MARKET WIRE)--Jan 5, 2009 -- GeneThera, Inc. (Other OTC:GTHR.PK - News) is in discussions with a public company traded on the Nasdaq for a potential merger or acquisition.
The Board of Directors at GeneThera believes a merger with a larger, more recognized company to be a great way to bring the company’s technology and latest developments to market. “Any merger will greatly enhance shareholder wealth and allow us to maintain control over our existing projects,” noted GeneThera’s Dr. Tony Milici.
GeneThera is currently in discussions with several other Nasdaq and NYSE development and distribution companies regarding the marketing of its E. Coli Vaccine as well as its Johne’s disease testing service. GeneThera recently announced it would start testing for Johne’s disease utilizing its Real Time PCR testing method. There are more than 1 million Johne’s tests currently conducted annually in the US using various methods. The number of cattle available to test is over 17 million. Real Time PCR is the most accurate test available, and GeneThera will have the only high-speed robotic laboratory created specifically for this purpose in the US.
“We believe we have ‘blockbuster opportunities,’ which are designed to protect the American consumers from food borne pathogens such as E. Coli, Mad Cow disease, and Johne’s disease,” Milici continued. “We will release partial income projections and other Joint Venture details in the near term, which will assist in determining value. As merger discussions progress the company will release more details.”
ABOUT GENETHERA, INC.
GeneThera, Inc. is a molecular biotechnology company located in Wheat Ridge, Colorado. The Company’s proprietary diagnostic solution is based on a genetic expression assay, GES(TM), a protocol designed to function on a highly automated Fluorogenic PCR platform. This platform enables GeneThera to offer tests that are presently not available from other technologies. The GES is designed for a host of individual diseases, the current priorities being Mad Cow disease, E. coli 0157:H7 and Johne’s disease. For more information, contact Dr. Tony Milici at 303-463-6371 or Al Goldsmith of The Goldsmith Group LLC at 303-838-4370.
This press release contains forward-looking statements, which are made pursuant to the Safe-Harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as “intends,” “believes,” and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company’s filings with the Securities and Exchange Commission. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.
Contact:
Contact:
Dr. Tony Milici 303-463-6371 Goldsmith Group 303-838-4370 JR Dopkin & Associates 516-884-3200
Source: GeneThera, Inc.
